奥利塞里丁临床应用的概述和前景
Kun Yi1, Wenjie Sun1, Wen Yu1
1Department of Anesthesiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, People's Republic of China.
Drug design, development and therapy
|July 2, 2025
概括
奥利塞里丁通过向μ-阿片类受体,提供强效的止痛药,副作用比传统阿片类药物少,向μ-阿片类受体. 这种G蛋白偏差激动剂显示出作为一种更安全的疼痛管理替代品的承诺,特别是在手术后.
科学领域:
- 药理学 药理学是指药理学的学科.
- 疼痛管理 疼痛管理
- 药物开发 药物开发
背景情况:
- 阿片类药物是有效的止痛药,但与成和不良影响等重大风险有关.
- 奥利塞里丁 (Olinvyk) 是一种针对μ-阿片类受体 (MOR) 的新型G蛋白偏差激动剂.
- 这种偏见的激进主义旨在将治疗效果与传统阿片类药物常见的不良事件分开.
研究的目的:
- 在各种手术环境中审查奥利塞里丁的疗效和安全性.
- 为了与传统阿片类药物比较oliceridine的概况.
- 为了确定未来的研究方向的奥利塞里丁.
主要方法:
- 对奥利塞里丁的临床前和临床数据的系统审查.
- 对奥利塞里丁的作用机制的分析,重点关注G蛋白与β-arrestin2通路的作用.
- 在手术疼痛管理中对奥利塞里丁与传统阿片类药物的疗效和安全性进行比较分析.
主要成果:
- 奥利塞里丁通过偏好的G蛋白激活MOR显示出强大的止痛作用.
- 减少oliceridine的β-arrestin2招募与较低的阿片类药物相关不良反应发生率相关.
- 临床试验表明,奥利塞里丁在治疗急性术后疼痛方面具有显著的潜力.
结论:
- 奥利塞里丁代表了阿片类药物镇痛的有前途的进步,提供了有效的缓解疼痛,并改善了安全性.
- 对于剂量优化,慢性疼痛应用和长期安全性评估,需要进一步的研究.
- 奥利塞里丁的独特机制为疼痛管理策略提供了潜在的范式转变.
更多相关视频
04:37Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
342
05:33Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
Published on: September 6, 2024
1.8K
相关概念视频
01:25Analgesia and Pain Management
817
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
817
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
908
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
908
01:22Opioid Receptors: Overview
2.0K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
2.0K
01:28Preclinical Development: Overview
4.9K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.9K
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
446
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
446
01:11Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K